Small cell lung cancer followed by adenocarcinoma a 2 cases report

HUANG Yanhua; XING Yanfei; MAO Minhua

doi:10.7619/jcmp.20222801

Journal of Clinical Medicine in Practice > 2023 > 27(1): 68-73. > DOI: 10.7619/jcmp.20222801

HUANG Yanhua, XING Yanfei, MAO Minhua. Small cell lung cancer followed by adenocarcinoma a 2 cases report[J]. Journal of Clinical Medicine in Practice, 2023, 27(1): 68-73. DOI: 10.7619/jcmp.20222801

Citation:

PDF (3644 KB)

Small cell lung cancer followed by adenocarcinoma a 2 cases report

Department of Respiratory and Critical Care Medicine, Qidong Hospital Affiliated to Nantong University, Qidong, Jiangsu, 226200

More Information

Received Date: September 06, 2022
Available Online: February 01, 2023

Graphical Abstract

Abstract

Abstract

Adenocarcinoma and small cell carcinoma were two common pathological types of lung cancer. The clinical data, pathological, immunohistochemical and genetic test results of two patients with small cell lung cancer (SCLC) after lung adenocarcinoma were reported. One case of SCLC transformation of epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitor (TKI) after treatment occurred. Another one case was synchronous multiple primary lung cancer, and the two cases were compared based on the literature. The prognosis of the two cases was poor, but the definite diagnosis and difference between them needed further exploration, and neuron specific enolase (NSE) may have predictive value for recurrent SCLC.
- lung adenocarcinoma,
- small cell lung cancer,
- small-cell lung cancer transformation,
- multiple primary lung cancer

FullText(HTML)

References (34)

References

[1]	WANG W X, XU C W, CHEN H F, et al. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: a multicenter retrospective study[J]. Lung Cancer, 2021, 155: 20-27. doi: 10.1016/j.lungcan.2021.03.006
[2]	MARCOUX N, GETTINGER S N, O'KANE G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes[J]. J Clin Oncol, 2019, 37(4): 278-285. doi: 10.1200/JCO.18.01585
[3]	陈澄, 黄建安, 王昌国, 等. 表皮生长因子受体突变的肺腺癌转化为小细胞肺癌患者特点探索[J]. 中华结核和呼吸杂志, 2021, 44(8): 723-728. doi: 10.3760/cma.j.cn112147-20201026-01063
[4]	张兰兰, 李向敏, 毛志远, 等. 2例肺腺癌EGFR-TKIs耐药后转化小细胞肺癌的病例报道及文献回顾[J]. 空军医学杂志, 2021, 37(3): 262-265. doi: 10.3969/j.issn.2095-3402.2021.03.021
[5]	赵盼, 桑蝶, 张育荣, 等. 肺腺癌转化为小细胞肺癌的临床特征分析[J]. 癌症进展, 2021, 19(7): 690-692, 740. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202107010.htm
[6]	LEE J K, LEE J, KIM S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas[J]. J Clin Oncol, 2017, 35(26): 3065-3074. doi: 10.1200/JCO.2016.71.9096
[7]	XIE T J, LI Y, YING J M, et al. Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)[J]. Transl Lung Cancer Res, 2020, 9(6): 2428-2439. doi: 10.21037/tlcr-20-1278
[8]	张爽, 李双, 崔雅楠, 等. 转化性小细胞肺癌研究进展[J]. 中国肺癌杂志, 2021, 24(10): 729-733. doi: 10.3779/j.issn.1009-3419.2021.101.28
[9]	NORKOWSKI E, GHIGNA M R, LACROIX L, et al. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology[J]. J Thorac Oncol, 2013, 8(10): 1265-1271. doi: 10.1097/JTO.0b013e3182a407fa
[10]	OSER M G, NIEDERST M J, SEQUIST L V, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin[J]. Lancet Oncol, 2015, 16(4): e165-e172. doi: 10.1016/S1470-2045(14)71180-5
[11]	SEQUIST L V, WALTMAN B A, DIAS-SANTAGATA D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J]. Sci Transl Med, 2011, 3(75): 75ra26.
[12]	VISVADER J E, LINDEMAN G J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions[J]. Nat Rev Cancer, 2008, 8(10): 755-768. doi: 10.1038/nrc2499
[13]	HAYASHI T, TAKAMOCHI K, KOHSAKA S, et al. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis[J]. Pathol Int, 2020, 70(5): 295-299. doi: 10.1111/pin.12919
[14]	NIEDERST M J, SEQUIST L V, POIRIER J T, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer[J]. Nat Commun, 2015, 6: 6377. doi: 10.1038/ncomms7377
[15]	AGGARWAL C, DAVIS C W, MICK R, et al. Influence of TP53 mutation on survival in patients with advanced EGFR-mutant non-small-cell lung cancer[J]. JCO Precis Oncol, 2018, 2018: PO. 18. 00107.
[16]	YU H A, SUZAWA K, JORDAN E, et al. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance[J]. Clin Cancer Res, 2018, 24(13): 3108-3118. doi: 10.1158/1078-0432.CCR-17-2961
[17]	SUTHERLAND K D, PROOST N, BROUNS I, et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung[J]. Cancer Cell, 2011, 19(6): 754-764. doi: 10.1016/j.ccr.2011.04.019
[18]	OFFIN M, CHAN J M, TENET M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes[J]. J Thorac Oncol, 2019, 14(10): 1784-1793. doi: 10.1016/j.jtho.2019.06.002
[19]	RAMIREZ M, RAJARAM S, STEININGER R J, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells[J]. Nat Commun, 2016, 7: 10690. doi: 10.1038/ncomms10690
[20]	韩解非. EGFR敏感突变肺腺癌患者在TKI耐药后出现小细胞肺癌转化的临床特征及分子机制[D]. 广州: 南方医科大学, 2016.
[21]	MC LEER A, FOLL M, BREVET M, et al. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers[J]. Lung Cancer, 2022, 167: 98-106. doi: 10.1016/j.lungcan.2022.01.008
[22]	ISHIOKA K, YASUDA H, HAMAMOTO J, et al. Upregulation of FGF9 in lung adenocarcinoma transdifferentiation to small cell lung cancer[J]. Cancer Res, 2021, 81(14): 3916-3929. doi: 10.1158/0008-5472.CAN-20-4048
[23]	ROMASZKO A M, DOBOSZYNSKA A. Multiple primary lung cancer: a literature review[J]. Adv Clin Exp Med, 2018, 27(5): 725-730. doi: 10.17219/acem/68631
[24]	陈瑜婷, 黄玲, 夏俊杰, 等. 多原发肺癌的诊疗进展[J]. 四川医学, 2022, 43(7): 722-726. doi: 10.16252/j.cnki.issn1004-0501-2022.07.018
[25]	洪子强, 金大成, 白向豆, 等. 多原发肺癌诊断与治疗的最新研究进展[J]. 中国全科医学, 2022, 25(27): 3435-3442. doi: 10.12114/j.issn.1007-9572.2022.0331
[26]	LIU Y, ZHANG J J, LI L, et al. Genomic heterogeneity of multiple synchronous lung cancer[J]. Nat Commun, 2016, 7: 13200. doi: 10.1038/ncomms13200
[27]	MA P F, FU Y J, CAI M C, et al. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer[J]. Nat Commun, 2017, 8(1): 823. doi: 10.1038/s41467-017-00963-0
[28]	李铭, 胡广原, 梅齐, 等. 晚期非小细胞肺癌化疗[J]. 实用临床医药杂志, 2017, 21(13): 26-28. doi: 10.7619/jcmp.201713007
[29]	王晓男, 郭华峰, 杨璐. 多层螺旋CT对非小细胞肺癌与小细胞肺癌的诊断分析[J]. 实用临床医药杂志, 2020, 24(23): 5-7. doi: 10.7619/jcmp.202023002
[30]	TARIQ S, KIM S Y, MONTEIRO DE OLIVEIRA NOVAES J, et al. Update 2021: management of small cell lung cancer[J]. Lung, 2021, 199(6): 579-587. doi: 10.1007/s00408-021-00486-y
[31]	承柯伟, 方晓明, 吴玉英. 3种血清指标水平与晚期肺腺癌化疗患者预后的相关性分析[J]. 实用临床医药杂志, 2020, 24(24): 10-12, 16. doi: 10.7619/jcmp.202024003
[32]	SUN A, DUROCHER-ALLEN L D, ELLIS P M, et al. Initial management of small-cell lung cancer (limited-and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review[J]. Curr Oncol, 2019, 26(3): e372-e384. doi: 10.3747/co.26.4481
[33]	YANG S, ZHANG Z, WANG Q M. Emerging therapies for small cell lung cancer[J]. J Hematol Oncol, 2019, 12(1): 47. doi: 10.1186/s13045-019-0736-3
[34]	BHALLA S, DOROSHOW D B, HIRSCH F R. Predictive biomarkers for immune checkpoint inhibitors in advanced non-small cell lung cancer: current status and future directions[J]. Cancer J, 2020, 26(6): 507-516. doi: 10.1097/PPO.0000000000000483

[1]	LI Ruibiao, REN Chengbo, WANG Cong, LI Yaru. Comparison of the efficacy of dosimetric parameters defined by different lung volume methods in predicting radiation pneumonitis in patients with non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(19): 5-8, 13. DOI: 10.7619/jcmp.20221246
[2]	ZHANG Weijie, ZHANG Ruochen, CHEN Yikun, LI Yue, HUANG Jian'an. Effects of ten-eleven translocation-2 on proliferation and migration as well as invasion of non-small cell lung cancer and its mechanism[J]. Journal of Clinical Medicine in Practice, 2021, 25(10): 24-28, 32. DOI: 10.7619/jcmp.20211711
[3]	WANG Xiaonan, GUO Huafeng, YANG Lu. Analysis of multi-slice spiral CT in diagnosis of non-small cell lung cancer and small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(23): 5-7. DOI: 10.7619/jcmp.202023002
[4]	WANG Zhishang, FENG Xiemin, TIAN Dongdong. Clinical study of DC-CIK cell combined with chemotherapy in the treatment of advanced non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2017, (15): 85-87,91. DOI: 10.7619/jcmp.201715023
[5]	WU Qiyong, QI Chunjian, CHEN Chen, WANG Yong. Effect of tumor-associated macrophages on promotion of proliferation and metastasis of non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2016, (9): 101-104. DOI: 10.7619/jcmp.201609029
[6]	WANG Sheng, ZHANG Rui, WANG Junfeng, ZHAO Hui. Expression and its significance of Th17 cell and IL-17 cell in peripheral blood of patients with non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2015, (23): 34-36. DOI: 10.7619/jcmp.201523011
[7]	ZHAO Dan. A comparative study of the efficacy of pemetrexed or docetaxel in combination with cisplatin as second-line treatment of advanced non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2015, (15): 34-37. DOI: 10.7619/jcmp.201515010
[8]	ZHOU Yuan, GAO Jing, LI Wei. Application of holistic nursing intervention on patients with non-small-cell lung cancer treated with chemotherapy[J]. Journal of Clinical Medicine in Practice, 2015, (8): 43-45. DOI: 10.7619/jcmp.201508014
[9]	QIAN Hong, SHEN Shuangshuang, LYU Yang, YANG Jinfeng. Expressions and correlation of P-ACC and COX-2 in tissues of patients with non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2014, (24): 30-32,56. DOI: 10.7619/jcmp.201424009
[10]	HAN Zhigang, YU Tingting, SHEN Hongli, Alimjan Saitiwaerdi. Study on the correlation of Napsin-A expression and EGFR genes in non-small cell lung cancer tissue[J]. Journal of Clinical Medicine in Practice, 2014, (13): 1-3. DOI: 10.7619/jcmp.201413001

Cited By

Cited by

Periodical cited type(9)

1.	马雪萍，王晓丽，阿里木江·司马义，徐桂萍. 腹股沟上髂筋膜阻滞复合全身麻醉对高龄髋关节置换患者术后谵妄发生的影响. 新疆医学. 2022(02): 131-134 .
2.	张宏，李淑萍. 老年患者髋关节置换术后谵妄的发生现状及其相关影响因素分析. 长春中医药大学学报. 2022(10): 1155-1159 .
3.	刘贵政，郑婷婷，杜斌. 老年髋部骨折患者术后谵妄发生现况及危险因素研究. 贵州医药. 2022(09): 1405-1406 .
4.	王秀环，鲍乐乐，马漪洁，陈宁宁. 不同麻醉方法对老年髋关节置换患者术后谵妄发生的影响. 广州医科大学学报. 2021(02): 40-44 .
5.	刘丹，杨万翔. 人文关怀护理对人工髋关节置换术后谵妄患者临床症状的影响. 中国当代医药. 2021(25): 270-272+276 .
6.	陈立红，徐芙蓉，叶洁玉，许华亮. 高龄骨科髋关节置换术后患者发生谵妄的危险因素分析. 现代医学与健康研究电子杂志. 2021(23): 115-118 .
7.	毛俊岚. 高龄患者髋关节置换术后谵妄1例的护理. 基层医学论坛. 2020(03): 420-421 .
8.	欧玉琼，吴建颖，周嫦娥. 以临床路径为指导的谵妄管理对老年股骨头置换术后患者的影响. 护理实践与研究. 2020(02): 86-88 .
9.	姜红卫. 骨科老年患者髋关节术后谵妄发生原因及疼痛干预护理进展. 系统医学. 2020(13): 196-198 .

Other cited types(1)

Get Citation

PDF

XML

Article views (277) PDF downloads (21) Cited by(10)

Turn off MathJax

Article Contents

Abstract

References

Small cell lung cancer followed by adenocarcinoma a 2 cases report